无并发症淋病抗生素治疗指南比较

doi:10.3760/cma.j.issn.0412-4030.2018.05.023

摘要/Abstract

摘要： 临床诊疗指南是针对特定的临床情况，系统制订出帮助医生作出恰当处理的推荐意见。指南需要基于对现有证据通过系统综述形成的证据以及对各种可选的干预方式进行利弊评价之后提出最优指导意见。临床诊疗指南为发达国家提供了比较合理、安全、规范、节约的医疗服务指导原则［1］。淋病是常见性传播疾病，由淋球菌感染所致，全球每年约有7 800万新发感染［2］。该病可以通过抗生素治愈，但是由于抗菌药物广泛应用、不正确使用甚至滥用，导致淋球菌耐药性不断出现变化。目前淋球菌几乎对曾经的一线治疗药物都发生了耐药：磺胺类药物、青霉素、四环素及喹诺酮类药物［3］。现今一线治疗药物为头孢曲松，但近年监测数据显示，淋球菌对头孢菌素类药物最低抑菌值呈现逐年上升趋势［4?6］，继2003年日本报道淋病患者头孢克肟治疗失败后，加拿大、英国、南非、奥地利及挪威等国也相继报道了头孢克肟治疗淋病失败的病例……

关键词: 淋病, 指南, 治疗

Key words: Gonorrhoea, Guideline, Treatment

韩燕尹跃平王千秋. 无并发症淋病抗生素治疗指南比较[J]. 中华皮肤科杂志, 2018, 51(5): 396-399.

Yue-ping YIN. Comparison of guidelines for antibiotic treatment of uncomplicated gonorrhea[J]. Chinese Journal of Dermatology, 2018, 51(5): 396-399.

参考文献 23

［1］	蒋朱明, 詹思延, 贾晓巍, 等. 制订/修订《临床诊疗指南》的基本方法及程序［J］. 中华医学杂志, 2016,96（4）:250⁃253. doi: 10.3760/cma.j.issn.0376⁃2491.2016.04.004.<br />
［2］	Newman L, Rowley J, Vander HS, et al. Global estimates of the prevalence and incidence of four curable sexually transmitted infections in 2012 based on systematic review and global reporting［J］. PLoS One, 2015,10（12）:e0143304. doi: 10.1371/journal.pone. 0143304.<br />
［3］	Skerlev M, Culav⁃Košcak I. Gonorrhea: new challenges［J］. Clin Dermatol, 2014,32（2）:275⁃281. doi: 10.1016/j.clindermatol.2013. 08.010.<br />
［4］	Papp JR, Abrams AJ, Nash E, et al. Azithromycin resistance and decreased ceftriaxone susceptibility in Neisseria gonorrhoeae, Hawaii, USA［J］. Emerg Infect Dis, 2017,23（5）:830⁃832. doi: 10.3201/eid2305.170088.<br />
［5］	Lahra MM, Enriquez RP, National Neisseria Network. Prince of Wales Hospital, Randwick, for The National Neisseria Network. Australian gonococcal surveil⁃lance programme, 1 July to 30 September 2016［J］. Commun Dis Intell Q Rep, 2017,41（1）:E109⁃E110.<br />
［6］	Yasuda M, Hatazaki K, Ito S, et al. Antimicrobial susceptibility of Neisseria gonorrhoeae in Japan from 2000 to 2015［J］. Sex Transm Dis, 2017,44（3）:149⁃153. doi: 10.1097/OLQ.0000000000000556.<br />
［7］	Ohnishi M, Saika T, Hoshina S, et al. Ceftriaxone⁃resistant Neisseria gonorrhoeae, Japan［J］. Emerg Infect Dis, 2011,17（1）:148⁃149. doi: 10.3201/eid1701.100397.<br />
［8］	Ohnishi M, Golparian D, Shimuta K, et al. Is Neisseria gonorrhoeae initiating a future era of untreatable gonorrhea?: detailed characterization of the first strain with high⁃level resistance to ceftriaxone［J］. Antimicrob Agents Chemother, 2011,55（7）:3538⁃3545. doi: 10.1128/AAC.00325⁃11.<br />
［9］	World Health Organization. Global action plan to control the spread and impact of antimicrobial resistance in Neisseria gonorrhoeae［EB/OL］. （2012）［2017⁃10⁃10］. http://apps.who.int/iris/bitstream/handle/10665/44863/9789241503501_eng.pdf; jse<br />
	ssionid=328FFA0906F2F0799A827B764DAC7BEB?sequence=<br />
1.	<br />
［10］	Japanese Society for Sexually Transmitted Diseases. Guidelines for the diagnosis and treatment of sexually transmitted diseases 2011［J］. Jpn J Sex Transm Dis, 2011,22Suppl: 52⁃59.<br />
［11］	Japanese Society for Sexually Transmitted Diseases. Guidelines for the diagnosis and treatment of sexually transmitted diseases 2016［J］. Jpn J Sex Transm Dis, 2016, 22Suppl: 51⁃58.<br />
［12］	Bignell C, Fitzgerald M. UK national guideline for the manage⁃ment of gonorrhoea in adults, 2011［J］. Int J STD AIDS, 2011,22（10）:541⁃547. doi: 10.1258/ijsa.2011.011267.<br />
［13］	Bignell C, Unemo M. 2012 European guideline on the diagnosis and treatment of gonorrhoea in adults［J］. Int J STD AIDS, 2013,24（2）:85⁃92. doi: 10.1177/0956462412472837.<br />
［14］	Public Health Agency of Canada. Canadian guidelines on sexually transmitted infections［EB/OL］. （2013⁃7）［2017⁃10⁃10］. https://www.canada.ca/en/public⁃health/services/infectious⁃diseases/sexual⁃health⁃sexually⁃transmitted⁃infections/canadian⁃guidelines/sexually⁃transmitted⁃infections/canadian⁃guidelines⁃sexually⁃transmitted⁃infections⁃34.html.<br />
［15］	The New Zealand Sexual Health Society. New Zealand guideline for the management of gonorrhoea, 2014, and response to the threat of antimicrobial resistance. 2014. http://www.regionalnet⁃work.ashm.org.au/wp⁃content/uploads/2016/04/new⁃zealand⁃guideline⁃for⁃the⁃management⁃of⁃gonorrhoea⁃2014⁃and⁃response⁃to⁃the⁃threat⁃of⁃antimicrobial⁃resistance.pdf.<br />
［16］	Workowski KA, Bolan GA. Centers for disease control and prevention sexually transmitted diseases treatment guidelines. 2015［J］. MMWR Recomm Rep, 2015,64（RR⁃03）:1⁃137.<br />
［17］	Australasian Sexual Health Alliance. Australian STI management guidelines for use in primary care. 2016. http://www.sti.guidelines.org.au/ sexually⁃transmissible⁃infections/ gonorrhoea#management. （assess in Oct 10, 2017）<br />
［18］	中国疾病预防控制中心性病控制中心, 中华医学会皮肤性病学分会性病学组, 中国医师协会皮肤科医师分会性病亚专业委员会. 梅毒、淋病、生殖器疱疹、生殖道沙眼衣原体感染诊疗指南（2014）［J］. 中华皮肤科杂志, 2014,47（5）:365⁃372. doi: 10.3760/cma.j.issn.0412⁃4030.2014.05.022.<br />
［19］	World Health Organization. WHO guidelines for the treatment of Neisseria gonorrhoeae. https://www.ncbi.nlm.nih.gov/pubmedhealth/ PMH0093492/.<br />
［20］	Newman LM, Moran JS, Workowski KA. Update on the manage⁃ment of gonorrhea in adults in the United States［J］. Clin Infect Dis, 2007,44（Suppl 3）:S84⁃101. doi: 10.1086/511422<br />
［21］	Chisholm SA, Mouton JW, Lewis DA, et al. Cephalosporin MIC creep among gonococci: time for a pharmacodynamic rethink?［J］. J Antimicrob Chemother, 2010,65（10）:2141⁃2148. doi: 10.1093/jac/dkq289.<br />
［22］	于瑞星, 尹跃平, 戴秀芹, 等. 头孢曲松和阿奇霉素体外抗淋球菌联合作用研究［J］. 中华皮肤科杂志, 2017,50（5）:364⁃366. doi: 10.3760/cma.j.issn.0412⁃4030.2017.05.012.<br />
［23］	Sathia L, Ellis B, Phillip S, et al. Pharyngeal gonorrhoea ⁃ is dual therapy the way forward?［J］. Int J STD AIDS, 2007,18（9）:647⁃648. doi: 10.1258/095646207781568556.<br />

[1]	梁源刘玲玲王珊赵作涛马琳向欣顾恒陈崑王华易红陈谨萍张金桃姚志荣郭一峰陈戟程颖朱学骏. 0.03%他克莫司软膏长期间歇维持治疗儿童特应性皮炎的多中心随机对照临床研究[J]. 中华皮肤科杂志, 2019, 52(8): 519-524.
[2]	路坦王珊王榴慧李萍舒虹申春平吴瑶罗珍缪丽敏王红兵焦磊田晶彭晓霞赵牧童刘盈聂晓璐马琳何黎. 一种含青刺果油等提取物的润肤剂改善儿童特应性皮炎缓解期临床症状的多中心、随机、平行对照临床研究[J]. 中华皮肤科杂志, 2019, 52(8): 537-541.
[3]	卢旭亚徐强李品川张朝晖. 下肢痛性溃疡诊疗进展[J]. 中华皮肤科杂志, 2019, 52(7): 510-514.
[4]	陈怡雯苏婷苏忠兰. 银屑病与STAT3[J]. 中华皮肤科杂志, 2019, 52(7): 502-505.
[5]	余丽娟吕中法. JAK抑制剂治疗斑秃的研究进展[J]. 中华皮肤科杂志, 2019, 52(5): 343-346.
[6]	周园陈韡王大光. 钳形甲的治疗进展[J]. 中华皮肤科杂志, 2019, 52(5): 364-367.
[7]	罗金成陈曙光刘文英徐艳宋志强. 自体全血注射对自体血清皮肤试验阳性的难治性慢性自发性荨麻疹患者嗜碱性粒细胞FcεRⅠ与CD63表达的影响[J]. 中华皮肤科杂志, 2019, 52(4): 241-247.
[8]	雷杰豪樊奇敏陈荣许爱娥. 白癜风患者窄谱中波紫外线治疗效果与光疗反应的关系及相关因素分析[J]. 中华皮肤科杂志, 2019, 52(4): 259-262.
[9]	中华医学会皮肤性病学分会银屑病专业委员会. 中国银屑病诊疗指南（2018简版）[J]. 中华皮肤科杂志, 2019, 52(4): 223-230.
[10]	中华医学会皮肤性病学分会红斑狼疮研究中心. 皮肤型红斑狼疮诊疗指南（2019版）[J]. 中华皮肤科杂志, 2019, 52(3): 149-155.
[11]	中国医师协会皮肤科医师分会规范化诊疗工作委员会中国医学装备协会皮肤病与皮肤美容专业委员会皮肤外科装备学组和皮肤光治疗学组. 窄谱中波紫外线家庭光疗临床应用专家共识[J]. 中华皮肤科杂志, 2019, 52(3): 156-161.
[12]	翟寒月宋益兴. 585 nm脉冲染料激光治疗儿童传染性软疣的临床观察[J]. 中华皮肤科杂志, 2019, 52(3): 195-197.
[13]	王刚. 皮肤科生物制剂的主要不良反应及对策[J]. 中华皮肤科杂志, 2019, 52(2): 77-80.
[14]	关欣张春雷. 英夫利西单抗长疗程治疗中重度寻常性银屑病的疗效评价[J]. 中华皮肤科杂志, 2019, 52(2): 86-89.
[15]	胡宇晴张建中. 特应性皮炎治疗药物研究进展[J]. 中华皮肤科杂志, 2019, 52(1): 57-60.